Eli Lilly and Company has received FDA approval for its IL-13 inhibitor, Ebglyss (lebrikizumab), to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 and above. Ebglyss joins a growing list of new drug approvals for Lilly, including Mounjaro, Zepbound, Omvoh, and Jaypirca, all contributing to the company’s strong financial performance. The company’s stock has outperformed the industry, sector, and S&P 500, with its new drugs driving significant revenue growth.
The FDA has approved Eli Lilly’s Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children with moderate-to-severe atopic dermatitis (eczema) that doesn’t respond well to topical treatments. Ebglyss targets eczema inflammation throughout the body, leading to significant improvement in skin dryness, itching, and irritation. The drug’s effectiveness was proven in clinical trials, with a substantial percentage of patients achieving clear or almost-clear skin and itch relief.
Louise Smith, a 36-year-old receptionist, experienced a severe eye eczema flare-up after using a new eye makeup concealer. The reaction caused months of agony, leaving her unable to wear makeup and forced to wear sunglasses constantly. After extensive research and trying numerous treatments, Smith finally found relief with Hydrosil Dry Eye Gel, a plant-based alternative to steroids. The gel, along with the brand’s concealer, helped Smith regain her confidence and normal eye appearance after two months.
Balmonds Skin Salvation is a popular cream among shoppers who suffer from hay fever and eczema. The cream is made from natural ingredients, including chamomile, calendula, chickweed, and organic hemp seed oil, which work together to soothe and repair the skin. Shoppers have praised the cream for its effectiveness in relieving redness, irritation, and itching, as well as its ability to improve the overall health of the skin.
Eczema, a chronic skin disease affecting children worldwide, has spiked in recent decades, particularly in industrialized nations. Research suggests that environmental factors, such as exposure to certain chemicals, play a significant role. Diisocyanates and xylene, common in synthetic materials, polyurethane, and exhaust fumes, have been linked to increased eczema risk. These chemicals can disrupt the skin’s microbiome, preventing the production of ceramides, essential for a healthy skin barrier. Reducing exposure to these chemicals, avoiding synthetic fabrics and harsh skincare products, and addressing microbial balance are crucial steps in managing eczema. Understanding the environmental triggers can help protect children from this increasingly prevalent condition.
Eczema, a chronic skin disease affecting 1 in 5 children in industrialized nations, has seen a sharp increase in rates since 1970. Researchers have identified two chemical classes, diisocyanates and xylene, which increased in production around the same time as the eczema spike. These chemicals are found in various products, including spandex, paint, and automobile exhaust, and have been linked to eczema in mice. Exposure to these chemicals may lead to a disruption in the skin microbiome, reducing the production of ceramides, which protect the skin from infection. To mitigate the risk of eczema, it’s recommended to avoid products containing isocyanates or xylene, particularly for children under 4. Using EPA resources to track local pollutants and improving microbial balance through probiotics and skin care practices can also be beneficial.
